{"groups":[{"description":"Participants received durvalumab monotherapy (1500 milligram \\[mg\\] for participants \\>30 kilogram \\[kg\\] in weight and a weight-based dosing equivalent to 20 mg/kg for participants \\<=30 kg in weight) via intravenous (IV) infusion once every 4 weeks (q4w), until clinical/Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"FG000","title":"Durvalumab"},{"description":"Participants received durvalumab in combination with tremelimumab (1500 mg durvalumab in combination with 75 mg tremelimumab for participants \\>30 kg in weight and a weight-based dosing equivalent to 20 mg/kg durvalumab in combination with 1 mg/kg tremelimumab for participants \\<=30 kg in weight) via IV infusion once q4w, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"FG001","title":"Durvalumab Plus Tremelimumab"},{"description":"Participants received matching placebo via IV infusion once q4w for 4 doses/cycles each, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"FG002","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"115"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"144"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"11"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"200"},{"groupId":"FG002","numSubjects":"111"}],"type":"Ongoing at the time of DCO"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"264"},{"groupId":"FG001","numSubjects":"200"},{"groupId":"FG002","numSubjects":"266"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"262"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"265"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"264"},{"groupId":"FG001","numSubjects":"200"},{"groupId":"FG002","numSubjects":"266"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Based on the results of the secondary objectives at the interim analysis (reviewed by an unblinded independent data monitoring committee \\[IDMC\\]), data for the D+T arm were to remain blinded to the Sponsor as pre-specified in the study's unblinding plan. Since the D+T arm was blinded at the time of posting the results from this interim analysis, results for that arm will be posted at the time of final analysis.","recruitmentDetails":"This Phase III, double-blind, placebo-controlled trial studied participants with limited stage small-cell lung cancer who had not progressed after concurrent chemoradiation therapy at 164 sites in 19 countries. Interim results are based on data cut-off (DCO) date of 15 January 2024. 730 participants were randomized; the first 600 in a 1:1:1 ratio to durvalumab monotherapy (D), durvalumab plus tremelimumab combination therapy (D+T) or placebo (P), the remaining in a 1:1 ratio to D or P."}